Home
ICCM
ICCM News

Latest IceCure Medical Ltd. (ICCM) News on December 22, 2024

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

PR Newswire

6 days ago

Data on IceCure's ProSense® Cryoablation for Low-Risk Breast Cancer Presented at Radiological Society of North America's 2024 Annual Meeting

IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results

PR Newswire

17 days ago

IceCure's ProSense® Cryoablation Safe and Effective in Destruction of Kidney Tumors with 88.7% Recurrence-Free Rate Based on Interim ICESECRET Study Results

IceCure Medical Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

Simply Wall St.

a month ago

IceCure Medical Third Quarter 2024 Earnings: EPS Beats Expectations, Revenues Lag

IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates

Zacks

a month ago

IceCure Medical Ltd. (ICCM) Reports Q3 Loss, Misses Revenue Estimates

IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation

PR Newswire

a month ago

IceCure Medical Reports 36% Sales Growth in the First Nine Months of 2024 Driven by Global Adoption of ProSense® Cryoablation

IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

PR Newswire

a month ago

IceCure's Next-Generation Multiprobe Cryoablation Technology Issued Notice of Allowance from Japan's Patent Office

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

PR Newswire

a month ago

IceCure Medical to Report Third Quarter 2024 Financial & Operational Results on November 26, 2024

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

PR Newswire

a month ago

IceCure's ProSense® Chosen for Breast Cryoablation Study Led by the Prestigious European Institute of Oncology with Sponsorship from the Italian Ministry of Health

IceCure’s cryoablation system for breast cancer treatment gains FDA panel support

Medical Device Network

a month ago

IceCure’s cryoablation system for breast cancer treatment gains FDA panel support

PR Newswire

a month ago

FDA Advisory Panel Votes in Favor of IceCure's ProSense® Cryoablation Benefit-Risk Profile in Early-Stage Low Risk Breast Cancer

Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders

PR Newswire

2 months ago

Upcoming FDA Advisory Panel for IceCure's ProSense® Marketing Authorization Receives Large Number of Public Comments from Stakeholders

IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System

PR Newswire

2 months ago

IceCure Receives Notice of Allowance from U.S. Patent and Trademark Office for its Next-Generation Cryoablation System

Alignment HealthCare Partners With Intermountain Health in Nevada

Zacks

2 months ago

Alignment HealthCare Partners With Intermountain Health in Nevada

IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference

PR Newswire

3 months ago

IceCure's ProSense® Featured in 6 Global Studies on Cryoablation of Breast Tumors at the 2024 European Society of Breast Imaging Conference

Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic

Zacks

3 months ago

Zacks.com featured highlights Adverum Biotechnologies, IceCure, DarioHealth, Energous and Virgin Galactic

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate

PR Newswire

3 months ago

IceCure's ICE3 5-Year Trial Results Published in the Peer Reviewed Annals of Surgical Oncology Journal: ProSense® Cryoablation Without Excision for Early-Stage, Low-Risk Breast Cancer Demonstrates 96.3% Recurrence Free Rate

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues

PR Newswire

3 months ago

Study Published in the British Journal of Radiology Demonstrates IceCure's ProSense® is a Safe Procedure with 97.7% Technical Success Rate in Treating Tumors of the Lung, Bone, and Soft Tissues

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

PR Newswire

3 months ago

IceCure Announces FDA Advisory Panel Meeting Date for Marketing Authorization of ProSense® in Early-Stage Low Risk Breast Cancer Scheduled for November 7, 2024

IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences

PR Newswire

4 months ago

IceCure to Meet Institutional Investors at the H.C. Wainwright and Lake Street Capital Markets Conferences

USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies

PR Newswire

4 months ago

USPTO Grants Notice of Allowance for Additional Patent on IceCure's Novel Cryogenic Pump Technology: Reinforces IceCure's Global IP Leadership in Cryoablation Technologies

IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates

Zacks

4 months ago

IceCure Medical Ltd. (ICCM) Reports Q2 Loss, Tops Revenue Estimates

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

PR Newswire

4 months ago

IceCure Medical Reports 20% Growth in ProSense® System and Probe Sales for the First Half of 2024; Reflects Continued Adoption in the U.S. and Other Global Markets

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery

PR Newswire

4 months ago

IceCure's ProSense® Destroyed 100% of Breast Cancer Tumors in Independent Study of Patients Who Chose Cryoablation Instead of Surgery

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024

PR Newswire

4 months ago

IceCure Medical to Report Second Quarter 2024 Financial & Operational Results on August 20, 2024

IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"

PR Newswire

4 months ago

IceCure Announces Positive Data from the Largest Multi-Institutional Study of its Kind: "Cryoablation of Primary Breast Cancer in Patients Ineligible for Clinical Trials"

IceCure presents hat-trick of positive trial data for cryoablation device

Medical Device Network

5 months ago

IceCure presents hat-trick of positive trial data for cryoablation device

99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society

PR Newswire

5 months ago

99.74% Recurrence Free Rate for Women with Breast Cancer Treated with IceCure's ProSense® Cryoablation System: Key Findings Delivered at 32nd Annual Meeting of the Japanese Breast Cancer Society

IceCure Medical receives Nasdaq compliance notice

Medical Device Network

5 months ago

IceCure Medical receives Nasdaq compliance notice

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

PR Newswire

5 months ago

IceCure Medical Announces Receipt of Nasdaq Minimum Bid Price Notification

IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint

Zacks

5 months ago

IceCure's (ICCM) ProSense Breast Cancer Study Meets Endpoint

European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer

PR Newswire

5 months ago

European Study Provides More Evidence Supporting IceCure's ProSense® is Safe & Effective Cryoablation Treatment for Metastatic and Recurrent Breast Cancer

IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod

Zacks

6 months ago

IceCure Medical (ICCM) New Cryoablation System Gets FDA Nod

FDA grants marketing authorisation for IceCure’s XSense Cryoablation System

Medical Device Network

6 months ago

FDA grants marketing authorisation for IceCure’s XSense Cryoablation System

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes

PR Newswire

6 months ago

U.S. Food and Drug Administration Grants Regulatory Clearance to IceCure for Next-Gen XSense™ Cryoablation System with CryoProbes

We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate

Simply Wall St.

6 months ago

We're Keeping An Eye On IceCure Medical's (NASDAQ:ICCM) Cash Burn Rate

IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024

PR Newswire

6 months ago

IceCure Medical to Provide Overview and Share Recent Progress at Northland Capital Markets Virtual Growth Conference on June 25, 2024

Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function

PR Newswire

6 months ago

Positive Data from IceCure's Kidney Cancer Clinical Study Presented at Interventional Radiology Conference: Minimally Invasive Approach Results in Shorter Hospitalization and Minor Impact on Renal Function

IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade

Zacks

7 months ago

IceCure Medical (ICCM) Moves to Buy: Rationale Behind the Upgrade

FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan

PR Newswire

7 months ago

FDA to Convene Advisory Panel for Review of IceCure's De Novo Marketing Clearance Request for ProSense®, Decision Expected Early 2025; Aligns with Commercial Readiness Plan

IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024

PR Newswire

7 months ago

IceCure Medical Maintains Positive Momentum and Reports Sales Growth for Cryoablation System in First Quarter of 2024

IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024

PR Newswire

7 months ago

IceCure Medical to Report First Quarter 2024 Financial & Operational Results on May 28, 2024

IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase

PR Newswire

7 months ago

IceCure Medical to Highlight Key Achievements and Provide Business Overview at A.G.P. / Alliance Global Partners' Virtual Healthcare Company Showcase

Here's Why It's Unlikely That IceCure Medical Ltd's (NASDAQ:ICCM) CEO Will See A Pay Rise This Year

Simply Wall St.

7 months ago

Here's Why It's Unlikely That IceCure Medical Ltd's (NASDAQ:ICCM) CEO Will See A Pay Rise This Year

Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally

PR Newswire

8 months ago

Independent Study Results in Japan Demonstrate Zero (0%) Breast Cancer Local Recurrence 5 Years Following Treatment with IceCure's ProSense®, Adding to Continued Positive Data Published Globally

IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA

Zacks

8 months ago

IceCure Medical (ICCM) Submits Final Cryoablation Data to FDA

IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer

PR Newswire

8 months ago

IceCure Medical Reports Final ICE3 Breast Cancer Cryoablation Trial Results of 100% Patient and Physician Satisfaction and 96.3% Recurrence Free Rate: Data Submitted to FDA Requesting Marketing Authorization to Treat Early-Stage Breast Cancer

IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript

Insider Monkey

9 months ago

IceCure Medical Ltd (NASDAQ:ICCM) Q4 2023 Earnings Call Transcript

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance

PR Newswire

9 months ago

IceCure Medical Reports Full Year 2023 Financial Results: Global ProSense® and Disposables Sales Increase 26% as Company Continues Transition to Commercial Phase and Expects to Submit ICE3 Breast Cancer Study Data to FDA this Month for Marketing Clearance

IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes

PR Newswire

9 months ago

IceCure Submits FDA Regulatory Filing for New XSense™ Cryoablation System with Cryoprobes

IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024

PR Newswire

9 months ago

IceCure Medical to Report 2023 Full Year Financial & Operational Results on April 3, 2024

IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy

PR Newswire

9 months ago

IceCure Medical Reports Positive Topline Results From ICE3 Cryoablation Breast Cancer Study: Achievement of 96.39% Recurrence Free Rate Brings Company One Step Closer to Providing Women a Non-Surgical Alternative to Lumpectomy

IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes

PR Newswire

9 months ago

IceCure Receives Notice of Patent Allowance in Japan for a Novel Cryogen Flow Control to Optimize Patient Outcomes

IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference

PR Newswire

10 months ago

IceCure Medical to Present at 34th Annual Oppenheimer Healthcare MedTech & Services Conference

IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024

PR Newswire

10 months ago

IceCure's ProSense® a Promising Alternative Treatment for Extra-Pelvis Endometriosis: Independent Study Presented at ECR 2024

Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop

PR Newswire

10 months ago

Fourth BRIIT Conference in India Features IceCure's ProSense® in Breast Cancer Imaging & Interventions Workshop

Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer

PR Newswire

10 months ago

Study Using IceCure's ProSense® Treatment Results in 100% Tumor Reduction in Early-Stage Breast Cancer

IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan

PR Newswire

10 months ago

IceCure's ProSense® to be Featured at Two Upcoming Medical Conferences in Japan

Associated Press Finance

a year ago

Unifi: Fiscal Q2 Earnings Snapshot

UNIFI®, Makers of REPREVE®, Announces Second Quarter Fiscal 2024 Results

Business Wire

a year ago

UNIFI®, Makers of REPREVE®, Announces Second Quarter Fiscal 2024 Results

U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer

PR Newswire

a year ago

U.S. FDA Grants IceCure Medical's Appeal: Reopens De Novo Classification Request for Marketing Authorization of ProSense® for Early-Stage Breast Cancer

TEAF Announces 2023 Fund Tax Characterization of Distributions, Release of Annual Report

ACCESSWIRE

a year ago

TEAF Announces 2023 Fund Tax Characterization of Distributions, Release of Annual Report

Associated Press Finance

a year ago

Penns Woods: Q4 Earnings Snapshot

GuruFocus.com

a year ago

Penns Woods Bancorp Inc (PWOD) Reports Mixed Results Amid Rising Interest Rates

Penns Woods Bancorp, Inc. Reports Fourth Quarter and Year Ended 2023 Earnings

GlobeNewswire

a year ago

Penns Woods Bancorp, Inc. Reports Fourth Quarter and Year Ended 2023 Earnings

IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class

PR Newswire

a year ago

IceCure Medical's Breast Cryoablation Gains Prominence in the U.S., as Society of Interventional Oncology Annual Meeting Features its First Breast Cryoablation Master Class

Chemung Financial Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Simply Wall St.

a year ago

Chemung Financial Full Year 2023 Earnings: Revenues Beat Expectations, EPS Lags

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

GlobeNewswire

a year ago

Maxim Group LLC to Host the 2024 Healthcare IT Virtual Conference on Wednesday, January 24th & Thursday, January 25th at 9:00 A.M. ET

Sono-Tek Third Quarter 2024 Earnings: Beats Expectations

Simply Wall St.

a year ago

Sono-Tek Third Quarter 2024 Earnings: Beats Expectations

IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation

PR Newswire

a year ago

IceCure Medical's ProSense® Featured at Indian Society of Vascular and Interventional Radiology Conference: Key Opinion Leaders Highlight Benefits of Cryoablation

IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

GlobeNewswire

a year ago

IceCure Medical Regains Compliance with Nasdaq Minimum Closing Bid Price Rule

Concrete Pumping Holdings Inc (BBCP) Reports Solid Growth in Q4 and Fiscal Year 2023

GuruFocus.com

a year ago

Concrete Pumping Holdings Inc (BBCP) Reports Solid Growth in Q4 and Fiscal Year 2023

Bassett Announces Regular Quarterly Dividend

GlobeNewswire

a year ago

Bassett Announces Regular Quarterly Dividend

UEI Announces QuickSet® Software Expansion for Better Entertainment and Increased Engagement through Personalization

Business Wire

a year ago

UEI Announces QuickSet® Software Expansion for Better Entertainment and Increased Engagement through Personalization

GreenPower Announces Delivery of 10 EV Star Cab and Chassis to Global Retailer in Canada

CNW Group

a year ago

GreenPower Announces Delivery of 10 EV Star Cab and Chassis to Global Retailer in Canada

UEI Announces a Better Smart Home Control Experience with a Complete Line-Up of White Label Smart Home Hubs & Sensors

Business Wire

a year ago

UEI Announces a Better Smart Home Control Experience with a Complete Line-Up of White Label Smart Home Hubs & Sensors

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results

PR Newswire

a year ago

IceCure Medical CEO Issues Letter to Shareholders & Reports Increase in Sales in Preliminary Unaudited 2023 Results

Surf Air Mobility Enters Agreements to Supply Electric Powertrains to Major Kenyan Cessna Caravan Operators Safarilink and Yellow Wings

Business Wire

a year ago

Surf Air Mobility Enters Agreements to Supply Electric Powertrains to Major Kenyan Cessna Caravan Operators Safarilink and Yellow Wings

Several Insiders Invested In Community West Bancshares Flagging Positive News

Simply Wall St.

a year ago

Several Insiders Invested In Community West Bancshares Flagging Positive News

New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response

PR Newswire

a year ago

New Study Reports IceCure's ProSense® Boosts Immune Response Against Cancer: Enhances CD8+ T Cell Response

Aeva Selected by Top Global Automotive OEM to Directly Supply LiDAR for its Series Production Program

Business Wire

a year ago

Aeva Selected by Top Global Automotive OEM to Directly Supply LiDAR for its Series Production Program

4 Bargain Tech Stocks to Enhance Portfolio Returns in 2024

Zacks

a year ago

4 Bargain Tech Stocks to Enhance Portfolio Returns in 2024

Sono-Tek Completes Senior Management Transition

GlobeNewswire

a year ago

Sono-Tek Completes Senior Management Transition

Despite Fast-paced Momentum, TransAct Technologies Incorporated (TACT) Is Still a Bargain Stock

Zacks

a year ago

Despite Fast-paced Momentum, TransAct Technologies Incorporated (TACT) Is Still a Bargain Stock

Surf Air Mobility Enters into Binding Terms for a $35.2 Million Mandatory Convertible Debenture with GEM Global Yield LLC

Business Wire

a year ago

Surf Air Mobility Enters into Binding Terms for a $35.2 Million Mandatory Convertible Debenture with GEM Global Yield LLC

One G. Willi-Food International Insider Raised Stake By 15% In Previous Year

Simply Wall St.

a year ago

One G. Willi-Food International Insider Raised Stake By 15% In Previous Year

Positive Signs As Multiple Insiders Buy Chimerix Stock

Simply Wall St.

a year ago

Positive Signs As Multiple Insiders Buy Chimerix Stock

Study Using IceCure's ProSense® Finds: "Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients"

PR Newswire

a year ago

Study Using IceCure's ProSense® Finds: "Cryoablation Allows the Ultimate De-escalation of Surgical Therapy for Select Breast Cancer Patients"

Here's Why We're Watching Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn Situation

Simply Wall St.

a year ago

Here's Why We're Watching Dianthus Therapeutics' (NASDAQ:DNTH) Cash Burn Situation

Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023

Business Wire

a year ago

Innate Pharma Shares Efficacy and Safety Phase 1 /2 Results of NK Cell Engager SAR443579 / IPH6101 Developed by Sanofi at ASH 2023

Renowned TV and Radio Personality, Former New York Prosecutor Judge Jeanine Pirro Partners with Byrna Technologies to Champion Its Non-Lethal Security Solutions

PR Newswire

a year ago

Renowned TV and Radio Personality, Former New York Prosecutor Judge Jeanine Pirro Partners with Byrna Technologies to Champion Its Non-Lethal Security Solutions

IceCure's ProSense® Deepens Regulatory Approval in India

PR Newswire

a year ago

IceCure's ProSense® Deepens Regulatory Approval in India

PR Newswire

a year ago

Both Pets and Pet Parents Feel the Strain of Separation Anxiety When Apart, According to a New Survey from PetMeds®

Cadiz Inc.'s (NASDAQ:CDZI) top owners are private companies with 35% stake, while 33% is held by institutions

Simply Wall St.

a year ago

Cadiz Inc.'s (NASDAQ:CDZI) top owners are private companies with 35% stake, while 33% is held by institutions

Zevia PBC (NYSE:ZVIA) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Zevia PBC (NYSE:ZVIA) Q3 2023 Earnings Call Transcript

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript

Insider Monkey

a year ago

Clearside Biomedical, Inc. (NASDAQ:CLSD) Q3 2023 Earnings Call Transcript

Business Wire

a year ago

Skillsoft to Report Third Quarter 2024 Financial Results on December 5th

GuruFocus.com

a year ago

The Beauty Health Co (SKIN) Faces Headwinds: Q3 Earnings Reveal Challenges and Revised Guidance

BeautyHealth Reports Third Quarter 2023 Financial Results

Business Wire

a year ago

BeautyHealth Reports Third Quarter 2023 Financial Results

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

GlobeNewswire

a year ago

Clearside Biomedical Announces Third Quarter 2023 Financial Results and Provides Corporate Update

PetMeds® Announces the Formation of Veterinarian Advisory Board

PR Newswire

a year ago

PetMeds® Announces the Formation of Veterinarian Advisory Board

Share on Social Networks: